Tasquinimod Is an Allosteric Modulator of HDAC4 Survival Signaling within the Compromised Cancer Microenvironment
Authors:
- 14 February 2013
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 73 (4) , 1386-1399
Abstract
Tasquinimod is an orally active antiangiogenic drug that is currently in phase III clinical trials for the treatment of castration-resistant prostate cancer. However, the target of this drug has remained unclear. In this study, we applied diverse strategies to identify the histone deacetylase HDAC4 as a target for the antiangiogenic activity of tasquinimod. Our comprehensive analysis revealed allosteric binding (Kd 10–30 nmol/L) to the regulatory Zn2+ binding domain of HDAC4 that locks the protein in a conformation preventing HDAC4/N-CoR/HDAC3 complex formation. This binding inhibited colocalization of N-CoR/HDAC3, thereby inhibiting deacetylation of histones and HDAC4 client transcription factors, such as HIF-1α, which are bound at promoter/enhancers where epigenetic reprogramming is required for cancer cell survival and angiogenic response. Through this mechanism, tasquinimod is effective as a monotherapeutic agent against human prostate, breast, bladder, and colon tumor xenografts, where its efficacy could be further enhanced in combination with a targeted thapsigargin prodrug (G202) that selectively kills tumor endothelial cells. Together, our findings define a mechanism of action of tasquinimod and offer a perspective on how its clinical activity might be leveraged in combination with other drugs that target the tumor microenvironment. Cancer Res; 73(4); 1386–99. ©2012 AACR.Keywords
All Related Versions
This publication has 51 references indexed in Scilit:
- HDAC4 Protein Regulates HIF1α Protein Lysine Acetylation and Cancer Cell Response to HypoxiaJournal of Biological Chemistry, 2011
- Sirtuin 1 Modulates Cellular Responses to Hypoxia by Deacetylating Hypoxia-Inducible Factor 1αMolecular Cell, 2010
- Targeting tumor angiogenesis with histone deacetylase inhibitorsCancer Letters, 2009
- c-Myc mediates a hypoxia-induced decrease in acetylated histone H4Biochimie, 2009
- Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancerNature Medicine, 2009
- The many roles of histone deacetylases in development and physiology: implications for disease and therapyNature Reviews Genetics, 2009
- PCAF is an HIF-1α cofactor that regulates p53 transcriptional activity in hypoxiaOncogene, 2008
- Hypoxia induces a novel signature of chromatin modifications and global repression of transcriptionMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2008
- Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylasesProceedings of the National Academy of Sciences, 2007
- Patterns and Emerging Mechanisms of the Angiogenic Switch during TumorigenesisCell, 1996